Systemic Lupus Erythematosus Archives - Page 3 of 40

Lesser Damage Accrual Among Patients Not Fulfilling the 2019 EULAR/ACR Criteria for SLE

By

May 8, 2020

Investigators determined the difference in outcomes in patients who achieved or did not achieve the 2019 EULAR/ACR criteria for SLE.

General Rheumatology

Hydroxychloroquine for SARS-CoV-2 Infection: How Did We Get Here?

By

David C. Helfgott, MD

May 8, 2020

Hydroxychloroquine is a less-toxic metabolite of the antimalarial drug chloroquine and is used as an immunomodulator for the treatment of autoimmune diseases.

Systemic Lupus Erythematosus

Updated EULAR/ERA-EDTA Recommendations for the Management of Lupus Nephritis

By

Rheumatology Advisor Contributing Writer

April 27, 2020

The EULAR/ERA-EDTA developed updated recommendations for the management of lupus nephritis.

doctor wearing face mask meeting with patient

General Rheumatology

ACR Develops Clinical Guidance for the Management of Rheumatic Diseases During the COVID-19 Pandemic

By

Meghna Rao

April 24, 2020

The American College of Rheumatology developed clinical guidance for rheumatology providers for the management of rheumatic diseases during the COVID-19 pandemic.

Systemic Lupus Erythematosus

Telitacicept Fast-Tracked for the Treatment of Systemic Lupus Erythematosus

By

Brian Park, PharmD

April 24, 2020

The FDA has granted Fast Track designation to telitacicept for the treatment of systemic lupus erythematosus.

PCT manifests when hepatic UROD activity is <20% of normal.1 As porphyrins accumulate in the liver, they are transported to the skin, leading to phototoxicity as light exposure causes the porphyrins to release photons.1 Subsequently, patients develop blisters on sun-exposed areas of their skin, particularly the hands, face, neck, and forearms. These areas are also prone to blisters and peeling after mild trauma. When the lesions scar, they may resemble systemic scleroderma. In some cases, lesions become painful. Patients may also have abnormal hair growth, skin thickening, and hypopigmentation. PCT is diagnosed when elevated porphyrins are detected in the plasma. Urine and fecal studies can confirm the diagnosis when they show similarly elevated porphyrin levels, with urine typically showing excess uroporphyrin and 7-carboxylate porphyrin and feces showing excess isocoproporphyrin.6 Patients with a PCT diagnosis should be tested for HCV if their status is unknown. Photo Credit: Dr Harout Tanielian/Science Source.

Rheumatoid Arthritis

Sustained Virologic Response to HCV Therapy Does Not Decrease Incidence of SLE or RA

By

Bradley van Paridon

April 20, 2020

Patients with chronic hepatitis C (HCV) achieving sustained virologic response to pegylated interferon plus ribavirin therapy did not exhibit an effect on the incidence of systemic lupus erythematosus (SLE) or rheumatoid arthritis.

Systemic Lupus Erythematosus

Risk for SLE in Patients With Idiopathic Thrombocytopenic Purpura

By

Vicki Moore, PhD

April 17, 2020

Patients with idiopathic thrombocytopenic purpura may have a higher risk of systemic lupus erythematosus and should be monitored for incidental lupus.

General Rheumatology

Chloroquine COVID-19 Trial Stopped After Patient Deaths

April 17, 2020

A study of chloroquine in novel coronavirus 2019 (COVID-19) patients was halted due to potentially deadly side effects.

Systemic Lupus Erythematosus

Low Frequency of Flares During and After Pregnancy in Patients With Inactive or Stable Lupus

By

Yellowlees Douglas, PhD

April 16, 2020

Researchers identified predictors of flares during and after pregnancy in patients with inactive or stable disease activity and characterized and estimated the frequency of postpartum flares.

Knee osteoarthritis linked to risk of hypertension

Systemic Lupus Erythematosus

Assessing the Effect of ACC/AHA Hypertension Definition on Atherosclerotic Vascular Events in SLE

By

Yellowlees Douglas, PhD

April 15, 2020

Researchers aimed to assess the effect of the 2017 American College of
Cardiology/American Heart Association guidelines definition of hypertension on atherosclerotic vascular events in systemic lupus erythematosus.